Pressure-test volume “leakage” from prescription to fill based on a combination of claims analysis and practice manager research exploring benefits verification, PA denial/appeal rates, financial assistance, adherence rates, and other factors

Interrogate cost of access questions ahead of LOE to determine the contracting required to maintain volume for your brand (or convert volume to a new brand) in the face of generic/biosimilar launches

Pressure-test patient and payer perceptions of value as you right-size list and net pricing strategies and channel priorities, including penetration into direct-to-patient channels and NDC switches or authorized generic launches

Capture payer preferences for net price and GTN across channels and accounts in the current and future-state market scenarios (e.g., competitor entry, policy evolution) using a matrix approach to pricing sensitivity analysis

Evaluate traditional as well as innovative contracting approaches as well as potential for add-on/supplemental payments under bundled or separate payment structures for hospital, medical, and pharmacy benefit products

Develop a clear and cohesive PIE narrative to engage with payers based on a deep understanding of product, market, and TA, and develop materials and train the field teams for PIE roll-out and compelling communication of the narrative

Craft an evidence-based model policy to position your product value proposition to payers in a format that simplifies their review processes, and act like a payer to anticipate coverage criteria through analog analysis and stakeholder research

Develop robust claims analyses of your target market both between and within lines of therapy to anticipate the effects of payer restrictions on downstream utilization (e.g., share of patients able to overcome different types/extent of ST)

Clarify roles and incentives for key decision-makers across channels, and identify barriers and opportunities to influence coverage and management decision-making during institutional formulary review and value assessment processes

Anticipate coverage, tiering, and quality of access as well as pricing, contracting, and GTN across key channels through competitor and analog benchmarking to maximize market access and net price

Optimize market access launch preparation for your pipeline through competitor and analog product benchmarking across business units, including Commercial/ Brand, Market Access, HEOR, Medical Affairs, and Government Affairs teams

Craft a dynamic pricing model for your product that evaluates the impact of potential pricing and contracting options by channel and account on stakeholders across the pharmaceutical procurement and reimbursement chains

Prioritize your indication launches by evaluating global market dynamics, including the timing and competitive impact of brand, generic, and biosimilar launches, on pricing and access potential for your portfolio products

Pressure-test the value of cost of care offsets through a mix of landscape and claims data (to establish high-level cost of care benchmarks) and stakeholder research (to clarify the influence of those benchmarks on pricing potential)

Pressure-test contracting strategies for cost recovery across settings of care. Evaluate reimbursement approaches to ensure that practice economic incentives align with prescriber demand.

Develop the value narratives that resonate with key “champions” of and “gatekeepers” to access as well as top-down “influencers” within organized customers (e.g., health systems, IDNs, ACOs, “pay-vider” networks)

Benchmark evidence packages for standard-of-care and late-stage pipeline therapies to develop or refine the target product profile to articulate differentiable value

Identify, articulate, and align on the payer value proposition of the asset, by channel and plan type, and relative to competitive therapies

Evaluate evidence needs (e.g., H2H, switching studies, ITC) and study timing on premium pricing and/or access potential